9,850 Shares in Zoetis Inc. $ZTS Bought by Twin Tree Management LP

Posted by George Bondi on Jun 9th, 2026

Twin Tree Management LP purchased a new position in shares of Zoetis Inc. (NYSE:ZTS – Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 9,850 shares of the company’s stock, valued at approximately $1,239,000.

Other large investors have also recently bought and sold shares of the company. Norges Bank acquired a new stake in shares of Zoetis in the 4th quarter worth $734,425,000. Vanguard Group Inc. lifted its stake in shares of Zoetis by 12.9% in the 4th quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock worth $6,011,802,000 after acquiring an additional 5,474,210 shares during the period. Nordea Investment Management AB lifted its stake in shares of Zoetis by 79.2% in the 4th quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock worth $622,222,000 after acquiring an additional 2,179,578 shares during the period. Montrusco Bolton Investments Inc. lifted its stake in shares of Zoetis by 256.7% in the 4th quarter. Montrusco Bolton Investments Inc. now owns 2,168,078 shares of the company’s stock worth $266,888,000 after acquiring an additional 1,560,314 shares during the period. Finally, Arrowstreet Capital Limited Partnership lifted its stake in shares of Zoetis by 83.4% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,697,827 shares of the company’s stock worth $394,746,000 after acquiring an additional 1,227,085 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Performance

NYSE:ZTS opened at $78.80 on Tuesday. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80. The firm has a 50-day moving average price of $99.76 and a two-hundred day moving average price of $115.24. Zoetis Inc. has a twelve month low of $72.38 and a twelve month high of $169.50. The company has a market capitalization of $33.03 billion, a P/E ratio of 13.07, a price-to-earnings-growth ratio of 1.24 and a beta of 0.75.

Zoetis (NYSE:ZTS – Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The firm had revenue of $2.26 billion for the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The business’s quarterly revenue was up 2.9% compared to the same quarter last year. During the same quarter last year, the firm earned $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, research analysts expect that Zoetis Inc. will post 6.88 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be issued a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date is Monday, July 20th. Zoetis’s payout ratio is presently 35.16%.

More Zoetis News

Here are the key news stories impacting Zoetis this week:

Positive Sentiment: Zoetis received UK approval for Lenivia (izenivetmab), a long-acting osteoarthritis pain therapy for dogs, which could support future product sales and help offset some legal-related negativity. Zoetis (ZTS) Receives UK Approval for Long-Acting Osteoarthritis Pain Therapy Lenivia
Neutral Sentiment: Multiple law firms, including Rosen Law Firm, Levi & Korsinsky, Glancy Prongay Wolke & Rotter, Robbins Geller, the Schall Law Firm, Bronstein Gewirtz & Grossman, and DJS Law Group, issued repeated reminders about the pending securities class action and the July 27 lead-plaintiff deadline. ROSEN, A LONGSTANDING LAW FIRM, Encourages Zoetis Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ZTS
Negative Sentiment: The class-action filings alleging securities-law violations and investor losses may increase legal costs, create headline risk, and keep pressure on Zoetis shares until more clarity emerges. Zoetis Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – ZTS

Analyst Ratings Changes

ZTS has been the subject of several recent analyst reports. BTIG Research restated a “buy” rating and issued a $160.00 target price on shares of Zoetis in a research note on Thursday, February 26th. Argus restated a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. Citigroup reduced their target price on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Leerink Partners restated a “market perform” rating on shares of Zoetis in a research note on Tuesday, March 10th. Finally, UBS Group reduced their price objective on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a research note on Friday, May 8th. Six research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $133.92.

Check Out Our Latest Stock Analysis on Zoetis

Insider Activity at Zoetis

In other Zoetis news, Director Michael B. Mccallister purchased 3,000 shares of Zoetis stock in a transaction on Monday, May 11th. The shares were purchased at an average cost of $77.76 per share, with a total value of $233,280.00. Following the completion of the transaction, the director directly owned 24,524 shares in the company, valued at approximately $1,906,986.24. This represents a 13.94% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Paul Bisaro purchased 2,000 shares of Zoetis stock in a transaction on Wednesday, May 13th. The shares were acquired at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the transaction, the director owned 27,862 shares of the company’s stock, valued at $2,114,168.56. This represents a 7.73% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last three months, insiders purchased 11,650 shares of company stock worth $886,384. 0.22% of the stock is owned by company insiders.

Zoetis Company Profile

(Free Report)

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.